A significant development has emerged in the rapidly expanding litigation surrounding GLP-1 receptor agonist drugs such as Ozempic. The U.S. Judicial Panel on Multidistrict Litigation (JPML) has officially created a new federal multidistrict litigation (MDL) focused specifically on claims that these medications caused non-arteritic anterior ischemic optic neuropathy (NAION) — a serious and often permanent […]
View PostTrabajamos en régimen de contingencia, lo que significa que no hay costos por adelantado y que no cobramos honorarios de abogado a menos que ganemos tu caso y recibas una compensación.













